Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)

Trial Identifier: 1439A-021
Sponsor: MSD
Start Date: June 2015
Primary Completion Date: March 2017
Study Completion Date: September 2023
Condition: Human Immunodeficiency Virus (HIV)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Results Plain Language Summary – EMEA German
Results Plain Language Summary – NA English
Results Plain Language Summary – EMEA German
Results Plain Language Summary - LA Spanish
Results Plain Language Summary – EMEA German
Results Plain Language Summary – EMEA Spanish
Results Plain Language Summary – EMEA French
Results Plain Language Summary - LA Portuguese
Results Plain Language Summary –NA French
Results Plain Language Summary – EMEA French
Results Plain Language Summary – EMEA Portuguese
Results Plain Language Summary – EMEA Dutch
Results Plain Language Summary – EMEA Danish
Results Plain Language Summary – EMEA Russian
Results Plain Language Summary-English

Trial Locations

No locations posted.